Wird geladen...
A product review of vedolizumab in inflammatory bowel disease
Vedolizumab is a monoclonal antibody to the α4β7 integrin that selectively reduces intestinal lymphocyte trafficking, thereby providing a safe and effective treatment option for patients with inflammatory bowel disease (IBD). This product review outlines the unique mechanism of vedolizumab in additi...
Gespeichert in:
| Veröffentlicht in: | Hum Vaccin Immunother |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Taylor & Francis
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6816403/ https://ncbi.nlm.nih.gov/pubmed/30897022 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2019.1591139 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|